- Home
- »
- Medical Devices
- »
-
Intravenous Infusion Pumps Market Size, Share Report, 2033GVR Report cover
![Intravenous Infusion Pumps Market (2026 - 2033)Report]()
Intravenous Infusion Pumps Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Volumetric Infusion Pumps, Syringe Infusion Pumps), By Disease Indication (Chemotherapy, Diabetes, Gastroenterology), By Region, And Segment Forecasts
Market Size, 2025
$6.6BMarket Estimate, 2026
$7.2BMarket Forecast, 2033
$13.0BCAGR, 2026–2033
8.9%Intravenous Infusion Pumps Market Summary
The global intravenous infusion pumps market size was valued at USD 6.6 billion in 2025 and is projected to grow from USD 7.2 billion in 2026 to USD 13.0 billion by 2033, growing at a CAGR of 8.9% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 51.0% in 2025. The increasing incidence of conditions such as cancer, diabetes, cardiovascular diseases, and respiratory illnesses necessitates the accurate administration of medications and therapies.
Key Market Trends & Insights
- By product: Volumetric infusion pumps segment held the largest revenue share of 16.8% in 2025.
- By disease indication: Pediatrics/neonatology segment held the largest revenue share of 26.4% in 2025.
Regional Highlights
- Largest regional market: North America (51.0% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (fastest CAGR, 2026-2033)
- By country: The U.S. held the largest share of North America in 2025.
Market Size & Forecast
- Market size in 2025: USD 6.6 Billion
- Estimated market size in 2026: USD 7.2 Billion
- Projected market size by 2033: USD 13.0 Billion
- CAGR (2026-2033): 8.9%
Infusion pumps are indispensable in this context, delivering precise dosages of vital treatments such as chemotherapy, antibiotics, and nutritional fluids. As these chronic conditions rise, the demand for infusion pumps continues to expand, highlighting their critical role in effective disease management.
Intravenous infusion pumps are used to administer medications, hormones, and nutritional fluids into the circulatory system through veins in controlled amounts. They are extensively used in clinical settings such as hospitals, nursing homes, and homes. A trained operator operates the pump by programming the rate and duration of fluid delivery using built-in software. Intravenous infusion pumps can deliver nutrients, hormones, antibiotics, chemotherapy drugs, and pain relievers.
The key factors driving the market's growth include increased incidences of chronic diseases, rapid escalation in the geriatric population, rising demand for ambulatory infusion pumps, and the burgeoning number of people undergoing surgical procedures. Intravenous infusion pumps are mainly used to administer critical fluids, including high-risk medication. Most infusion pumps are equipped with safety features and in-built alarms for operator alerts intended to activate in the event of a problem. Many conditions, such as immune deficiencies, cancer, and congestive heart failure, cannot be treated with oral medications and require infusion therapy.
As individuals age, they are more susceptible to chronic illnesses that require complex medication regimens. Infusion pumps are particularly beneficial in outpatient and home care settings, enabling safe and accurate drug delivery to elderly patients. The demographic shift towards an older population amplifies the adoption of infusion pumps, ensuring that healthcare providers can effectively meet this vulnerable group's specific needs. According to the World Health Organization, life expectancy at birth increased to 73.3 years in 2024, up by 8.4 years since 1995. Moreover, the global population aged 60 and older is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030.
Technological advancements in infusion pump capabilities further bolster market demand. The emergence of smart infusion pumps equipped with wireless connectivity, electronic health record (EHR) integration, and automated programming enhances patient safety and operational efficiency. These innovations minimize medication errors, streamline workflows, and promote adherence to treatment protocols, encouraging healthcare facilities to invest in these advanced devices. Consequently, the integration of cutting-edge technology into infusion pumps is paving the way for wider adoption in clinical practice.
Market Dynamics
The increasing prevalence of chronic diseases, rising surgical procedures, and growing demand for precise and continuous drug delivery across hospital, ambulatory, and home care settings. The expanding geriatric population, increasing adoption of home-based infusion therapies, and rising focus on patient safety are further supporting market growth. In addition, technological advancements such as smart infusion pumps with dose error reduction systems and wireless connectivity, coupled with growing healthcare investments and improving healthcare infrastructure, are expected to drive market expansion over the forecast period.
The rising volume of hospital admissions, critical care cases, and surgical interventions is fueling demand for infusion pumps. These devices are widely used for anesthesia administration, fluid management, pain control, and post-operative care, making them indispensable across acute care settings. According to the Healthcare Financial Management Association May 2025 study found that annual ED visits across 123 rated hospitals rose from approximately 108,000 in 2020 to nearly 152,000 in 2024, representing a 40% increase. Although ED volumes declined by 8% in 2020 due to COVID-19-related disruptions, patient visits rebounded strongly and surpassed pre-pandemic levels by 2023, reflecting the sustained recovery and increasing utilization of emergency healthcare services.
The growing adoption of home healthcare and ambulatory infusion services is a key driver of the intravenous infusion pumps market. Rising healthcare costs, increasing prevalence of chronic diseases, and the need to minimize hospital stays have accelerated the shift toward home-based care settings. Intravenous infusion pumps enable the safe and precise administration of medications, fluids, and nutrients outside traditional hospital environments, making them essential for managing conditions such as cancer, diabetes, and chronic pain.
Technological advancements in portable and connected infusion devices are further supporting the expansion of home and ambulatory care services. Manufacturers are increasingly introducing smart infusion solutions with enhanced safety and remote monitoring capabilities to improve patient outcomes and reduce healthcare burden. For instance, in April 2024, Baxter International Inc. received U.S. FDA clearance for its Novum IQ Large Volume Infusion Pump with Dose IQ Safety Software, strengthening its connected infusion therapy portfolio across multiple care settings. Such developments are expected to support continued market growth over the forecast period.
The high cost associated with advanced infusion pump systems and their maintenance is expected to restrain the growth of the intravenous infusion pumps market. Smart infusion pumps integrated with dose error reduction software, wireless connectivity, and interoperability capabilities involve substantial capital investments. In addition, recurring expenses related to software updates, preventive maintenance, system integration, and staff training further increase the total cost of ownership.
The cost burden is particularly significant for small and mid-sized healthcare facilities and providers in emerging economies with constrained healthcare budgets. As a result, healthcare institutions in cost-sensitive regions often delay the replacement of conventional infusion systems or limit investments in advanced technologies, thereby impacting the global adoption of next-generation intravenous infusion pumps.
Market Concentration & Characteristics
The industry growth stage is high, and the pace of the market growth is accelerating. The emergence of smart infusion pumps equipped with advanced software minimizes medication errors through features such as drug libraries and wireless connectivity, thus enhancing workflow efficiency and safety in clinical settings.
Mergers and acquisitions are significantly prevalent within the parent market as companies strive to enhance their technological capabilities and market presence. Major industry players such as ICU Medical and Baxter International engage in strategic partnerships and acquisitions, facilitating innovation, accelerated product development, and enhanced distribution channels to meet rising market demands.
Regulatory frameworks play a crucial role in the intravenous infusion pump market by ensuring the safety and efficacy of products. Stringent, timely approvals from entities such as the U.S. Food and Drug Administration (FDA) enhance market acceptance and product development, thereby influencing innovation trajectories within the industry. In August 2024, the FDA expanded the Insulet SmartAdjust technology’s indications, enabling automated insulin dosing for adults with type 2 diabetes in the U.S.
Though intravenous infusion pumps are essential for accurate drug delivery, alternatives such as manual infusion techniques, syringe pumps, and wearable delivery systems exist. However, manual methods lack the precision of smart pumps, leading to their decline in favor of advanced solutions, which remain vital for continuous therapy in home healthcare settings.
Demographic shifts, healthcare investments, technological progress, and facilitative regulatory frameworks determine regional expansion in the market. North America and Europe currently exhibit market dominance in innovation, whereas the Asia Pacific region demonstrates the most rapid growth, attributed to its dynamic healthcare evolution and demographic transformations. Emerging markets are anticipated to experience future market expansion with improvements in infrastructure and access to sophisticated therapeutic modalities.
Analyst Perspective
The intravenous infusion pumps market is expected to witness steady growth, driven by the rising prevalence of chronic diseases, increasing surgical procedures, and growing demand for accurate drug delivery systems across hospital and home care settings. The expanding adoption of ambulatory and home healthcare services, coupled with the increasing use of infusion therapies for oncology, diabetes, and pain management, is further supporting market growth. Technological advancements such as smart infusion pumps with dose error reduction systems, wireless connectivity, and integration with electronic health records are enhancing patient safety and workflow efficiency. Market participants are focusing on product innovation and digital integration to strengthen their competitive position and address evolving healthcare needs.
Product Insights
Based on product, the volumetric infusion pumps segment held the largest revenue share of over 16.8% in 2025. Volumetric infusion pumps, utilizing electronic peristaltic pressure for accurate and continuous fluid delivery, are crucial in various healthcare settings for administering medications, nutrients, and pain relievers. Their efficacy in delivering large volumes precisely is vital in managing chronic diseases such as cancer and diabetes and in surgical procedures. The integration of advanced technologies and drug libraries by key players further enhances their utility.
Insulin infusion pumps are expected to grow at the fastest CAGR of 9.5% over the forecast period. The global rise in diabetes prevalence, primarily due to aging populations, unhealthy lifestyles, and increasing obesity rates, has driven insulin pump demand. WHO data published in March 2024 indicated that, in 2022, approximately 43.0% of adults were overweight, with 16.0% classified as obese, both significant risk factors for type 2 diabetes. Insulin pumps offer advantages over traditional delivery methods, providing continuous subcutaneous insulin infusion (CSII) that enhances glycemic control. Furthermore, next-generation pumps featuring continuous glucose monitoring and AI-driven adjustments further improve patient outcomes, fueling the growth of home-based diabetes management solutions.
The ambulatory infusion pumps, which are used to deliver liquid nutrients and medications to a patient in emergencies and chronic conditions, contributed a significant market share in 2025. These pumps are widely favored for the delivery of nutrients and medications. The availability of other pumps such as patient-controlled analgesia (PCA) pumps, insulin pumps, and smart pumps will contribute to the supplementary growth of this segment. The rising demand for enteral and syringe pumps contributes to the burgeoning preference for the intravenous infusion pump, leading to segment growth.
Disease Indication Insights
Based on disease indication, the pediatrics/neonatology segment held the largest revenue share of over 26.4% in 2025. The market has been segmented based on disease indication into chemotherapy, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, hematology, and others. According to the CDC, 1 in every 33 babies born in the U.S. is diagnosed with a congenital disability each year. Neonatology focuses on acute conditions in newborns, such as prematurity and congenital malformations. Effective, cost-efficient care and proper nutrition post-birth can reduce preterm births by nearly three-quarters. Moreover, older children face diseases such as neuroblastoma and Gaucher disease, which necessitate advanced infusion pumps for accurate medication delivery and to reduce overdose risks.
Chemotherapy is projected to grow at the fastest CAGR of 10.1% over the forecast period. In 2024, the American Cancer Society projected over 2 million new cancer cases and 611,720 cancer deaths in the U.S. While 30%-50 % of cancers can be prevented through risk mitigation and early diagnosis, treatment for malignant tumors often requires chemotherapy, administered intravenously or via capsules. In November 2024, a randomized phase 2 clinical trial by the University of Iowa Health Care demonstrated that adding high-dose intravenous vitamin C to chemotherapy doubled the overall survival of late-stage metastatic pancreatic cancer patients from eight months to 16 months. Such developments necessitate precise drug delivery through intravenous infusion pumps, driving market growth due to the increasing cancer prevalence.
The hematology segment is estimated to grow significantly over the forecast period. With the rising incidences of surgeries and blood cancer (hemophilia), the demand for intravenous infusion pumps has surged in hematology. These pumps are used for treatments such as blood transfusion, which is expected to increase in the coming years. Intravenous pumps are used for hematology as they are the only way blood can be transfused into a patient’s body in a precise, compact, and continuous manner. Moreover, it can regulate manual control or in an automated manner, avoiding the risk of failure during the treatment.
Regional Insights
North America dominated the intravenous infusion pumps market with the largest revenue share of 51.0% in 2025. The increasing Incidence of chronic diseases, an increasing number of surgical procedures performed, well-developed & increasing R&D, and escalating adoption of advanced technology in infusion pumps contributed to the growth the of intravenous pumps industry in this region.
In April 2024, Mackenzie Health (Canada) launched BD Alaris EMR Interoperability, a first-of-its-kind technology in Canada. This system facilitates two-way communication between IV pumps and patient EMRs, aiming to reduce medication errors and streamline workflows.
U.S. Intravenous Infusion Pumps Market Trends
The intravenous infusion pumps market in the U.S. held the largest share in the North America region in 2025, fueled by the high prevalence of chronic diseases, including cancer and diabetes. The country’s significant diabetes rates are linked to poor lifestyle choices and a stressful work environment. According to the Heart Failure Society of America’s (HFSA) Heart Failure Epidemiology and Outcomes Statistics report 2024, approximately 6.7 million Americans over the age of 20 are currently living with heart failure and is projected to rise to 8.7 million by 2030. Consequently, rising cardiovascular and chronic respiratory diseases, an aging population, and increasing surgical procedures are expected to boost demand for infusion pumps. Stricter government regulations and improved standards of care also contribute to market growth, alongside new product launches and FDA approvals.
Europe Intravenous Infusion Pumps Market Trends
Europe intravenous infusion pumps market held substantial market share in 2025. Most European countries boast well-developed healthcare infrastructures, facilitating the adoption of advanced patient care technologies. The market was driven by a growing burden of chronic diseases such as cancer and diabetes, an increasing number of surgical procedures, a rapid rise in the geriatric population, and significant government support.
Asia Pacific Intravenous Infusion Pumps Market Trends
Asia Pacific intravenous infusion pumps market is expected to register the fastest CAGR of 9.5% in the forecast period. Asian countries are population-dense with an elevated burden of chronic diseases such as diabetes, cardiovascular illnesses, and cancer. These countries are also popular for their low cost of treatment and surgeries, thus being a preferred market for medical tourism. Countries such as China, Japan, and India are emerging economies with well-developed healthcare infrastructure and facilities.
Japan's intravenous infusion pumps market is projected to grow at the fastest CAGR over the forecast period. The country is experiencing a rising median age due to declining mortality and increased life expectancy. This demographic shift has led to a growing prevalence of chronic diseases, highlighting the need for advanced infusion therapies.
Key Intravenous Infusion Pumps Company Insights
The market players are strategically utilizing drivers such as a shift in technology, automation, standardized dosing, and the extensive adoption of advanced healthcare technology for improved healthcare services. Moreover, major players often opt for geographical expansion to retain market share and adopt mergers, acquisitions, and new product launches to widen their portfolio.
-
Fresenius Kabi AG is a global manufacturer of intravenous infusion pumps, providing a comprehensive array of syringe and volumetric pumps designed for accurate drug and fluid delivery in hospital and ambulatory settings. Its systems incorporate safety technologies, medication error reduction software, and various IV disposables and accessories.
-
Tandem Diabetes Care, Inc. specializes in insulin infusion pumps for effective diabetes management. Its innovative t:slim X2 pump, featuring Control-IQ technology, offers user-friendly, connected insulin delivery systems that integrate continuous glucose monitoring and automated insulin dosing for individuals with diabetes.
Key Intravenous Infusion Pumps Companies:
The following key companies have been profiled for this study on the intravenous infusion pumps market.
-
Baxter
-
B. Braun Medical Inc.
-
Medtronic
-
Micrel Medical Devices SA
-
Boston Scientific Corporation
-
Cardinal Health
-
Fresenius Kabi AG
-
ICU Medical, Inc.
-
F. Hoffmann-La Roche Ltd
-
Tandem Diabetes Care, Inc.
-
Terumo Corporation
-
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-
Moog Inc.
- IRadimed Corporation
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Baxter, B. Braun Medical, Medtronic, Boston Scientific, etc.)
- Focus on expanding infusion pump portfolios through continuous product innovation, integration of smart pump technologies, and enhancement of medication safety features.
- Advanced technological capabilities, including wireless connectivity, dose error reduction systems, and integration with hospital information systems.
- Exposure to stringent regulatory requirements and product recall risks associated with device safety issues.
Emerging Players (Micrel Medical Devices SA, Tandem Diabetes Care, IRadimed Corporation)
- Focus on specialized infusion pump applications such as ambulatory infusion, insulin delivery, MRI-compatible systems, and cost-effective infusion technologies.
- Strong expertise in specific infusion therapy applications and ability to offer customized, user-friendly solutions.
- Limited global market presence and lower financial resources compared to diversified medical device leaders.
Recent Developments
-
In April 2025, Tandem Diabetes Care launched the Control-IQ+ insulin delivery technology in the U.S. This automated system expands accessibility to adults with type 2 diabetes and children aged two and older with type 1 diabetes.
-
In April 2025, ICU Medical received FDA 510(k) clearance for its new Plum Solo single-channel infusion pump and updated Plum Duo, expanding its IV Performance Platform with enhanced accuracy and data capabilities.
-
In November 2024, Boston Scientific announced an agreement to acquire Intera Oncology, aiming to broaden the company’s interventional oncology portfolio with Intera’s hepatic artery infusion pump technology for treating liver-dominant metastases.
-
In November 2024, ICU Medical, Inc. and Otsuka Pharmaceutical Factory (Japan) announced a joint venture to bolster IV solutions manufacturing and innovation within the North American market.
-
In October 2024, B. Braun Medical announced plans to increase its intravenous saline fluids production by 20% at its Irvine, California, and Daytona Beach, Florida facilities to address supply demands.
-
In April 2024, Baxter obtained FDA clearance for its Dose IQ Safety Software and Novum IQ large volume infusion pump, integrating both infusion modalities.
-
In January 2024, embecta Corp. announced the submission of a 510(k) premarket filing to the U.S. FDA for its proprietary disposable insulin delivery patch pump, designed to address the needs of individuals with type 2 diabetes.
Intravenous Infusion Pumps Market Report Scope
Report Attribute
Details
Market size in 2025
USD 6.6 billion
Market size value in 2026
USD 7.2 billion
Revenue forecast in 2033
USD 13.0 billion
Growth rate
CAGR of 8.9% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, disease indication, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Denmark, Sweden, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, Saudi Arabia, South Africa, UAE, Kuwait, Israel, Egypt, Netherlands, Belgium, Switzerland, Russia, Malaysia, New Zealand, Singapore, Philippines, Colombia, Chile
Key companies profiled
Baxter; B. Braun Medical Inc.; Medtronic; Micrel Medical Devices SA; Boston Scientific Corporation; Cardinal Health; Fresenius Kabi AG; ICU Medical, Inc.; F. Hoffmann-La Roche Ltd; Tandem Diabetes Care, Inc.; Terumo Corporation; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Moog Inc.; IRadimed Corporation
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Intravenous Infusion Pumps Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global intravenous infusion pumps market report based on product, disease indication, and region:
-
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Volumetric Infusion Pumps
-
Syringe Infusion Pumps
-
Insulin Infusion Pumps
-
Enteral Infusion Pumps
-
Ambulatory Infusion Pumps
-
Patient-Controlled Analgesia Infusion Pumps
-
Implantable Infusion Pumps
-
Others
-
-
Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
-
Chemotherapy
-
Diabetes
-
Gastroenterology
-
Analgesia/Pain Management
-
Pediatrics/Neonatology
-
Hematology
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Netherlands
-
Belgium
-
Switzerland
-
Russia
-
-
Asia Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Thailand
-
Malaysia
-
New Zealand
-
Singapore
-
Philippines
-
-
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Chile
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
Israel
-
Egypt
-
-
Research Methodology
The intravenous infusion pumps market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each intravenous infusion pumps segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment- Product
Revenue Capture Definition
Volumetric Infusion Pumps
Revenue generated from volumetric infusion pump systems designed to deliver precise volumes of fluids, medications, nutrients, and blood products intravenously over a specified period. These pumps are widely used in hospitals, ambulatory care settings, and home healthcare environments for continuous and intermittent infusion therapies requiring accurate fluid administration.
Syringe Infusion Pumps
This segment captures income from infusion devices that administer controlled quantities of fluids or medications using syringe-based delivery mechanisms. These pumps are commonly employed in critical care, anesthesia, neonatal care, and other clinical applications requiring highly accurate low-volume infusion.
Insulin Infusion Pumps
Market value in this category stems from portable infusion systems used for the continuous subcutaneous administration of insulin in patients with diabetes. These devices enable precise insulin delivery, support intensive glycemic management, and facilitate improved disease control in both clinical and home care settings.
Enteral Infusion Pumps
Revenue originates from pumps specifically designed to deliver nutritional formulations, fluids, and medications directly into the gastrointestinal tract through enteral feeding tubes. Such devices are extensively used in hospitals, long-term care facilities, and home healthcare settings for patients unable to consume food orally.
Ambulatory Infusion Pumps
This segment reflects earnings from lightweight, portable infusion devices that allow patients to receive medications while maintaining mobility and carrying out daily activities. Ambulatory pumps are frequently utilized for chemotherapy, pain management, antibiotic therapy, and other long-term infusion treatments administered outside traditional hospital settings.
Patient-controlled Analgesia (PCA) Infusion Pumps
Revenue derived from infusion systems that enable patients to self-administer predetermined doses of analgesic medications within programmed safety limits. These pumps are primarily used for postoperative pain management, cancer-related pain, and chronic pain treatment in both inpatient and outpatient settings.
Implantable Infusion Pumps
This segment captures income from surgically implanted pump systems designed for the long-term delivery of medications directly to targeted anatomical sites. These devices are commonly used for chronic pain management, spasticity treatment, chemotherapy administration, and other conditions requiring sustained drug delivery.
Others
Includes revenue generated from additional intravenous infusion pump systems not classified under major product categories, encompassing specialized infusion devices developed for niche therapeutic applications and specific clinical requirements.
Segment- Disease Indication
Revenue Capture Definition
Chemotherapy
Revenue generated from intravenous infusion pumps used for the controlled administration of chemotherapeutic agents in oncology care. These devices facilitate accurate dosing, prolonged drug delivery, and improved safety during cancer treatment protocols across hospital and outpatient settings.
Diabetes
This segment reflects income from infusion pump technologies utilized in diabetes management, particularly for continuous insulin delivery aimed at maintaining optimal glycemic control and improving patient outcomes.
Gastroenterology
Market value in this category stems from infusion pumps used in gastrointestinal disease management, including enteral nutrition delivery, hydration therapy, and administration of medications for chronic digestive disorders.
Analgesia/Pain Management
Revenue originates from infusion pump systems employed for the administration of analgesics and anesthetic agents in acute, postoperative, cancer-related, and chronic pain management applications.
Pediatrics/Neonatology
This segment captures earnings from infusion pumps designed or utilized for neonatal and pediatric patients requiring highly precise and low-volume administration of medications, fluids, and nutritional support.
Hematology
Demand within this category is driven by the use of infusion pumps for administering blood products, clotting factors, biologics, and supportive therapies used in the treatment of hematological disorders.
Others
Includes revenue from infusion pump applications across additional therapeutic areas such as infectious diseases, cardiology, immunology, endocrinology, and other clinical indications requiring controlled intravenous drug delivery.
Estimation Model
Top-Down
Parent Market
Segmentation
Validation
Forecasting
Commodity Flow Analysis
Parent Market & Penetration-Based Analysis
Country-Level Segment Share Modeling
Data Triangulation & Validation Model
Forecasting & CAGR Modeling
Market size was estimated by analyzing revenues generated by key intravenous infusion pump manufacturers, supported by company annual reports, investor presentations, regulatory filings, distributor insights, and premium industry databases. Revenue contributions from private and regional companies were assessed through secondary research and validated through primary interviews to derive the overall market value.
The demand-side analysis for the IV infusion pumps market is conducted by evaluating the adoption and utilization of infusion pumps across key end-user settings, patient populations, and therapy areas. The methodology focuses on estimating the number of infusion pumps required based on healthcare infrastructure, disease burden, treatment volumes, and infusion therapy utilization rates.
Market shares for product, and disease indication segments were derived using country-specific healthcare infrastructure, hospitalization rates, surgical procedure volumes, chronic disease burden, oncology treatment volumes, and adoption of smart infusion technologies. Weighted average calculations were applied to determine regional and global segment distributions.
Market estimates were validated through triangulation of secondary research, primary interviews, company-level revenue assessments, hospital procurement trends, end-user demand analysis, and infusion therapy utilization data to ensure consistency and accuracy across all market segments and geographies.
Market forecasts were developed using historical demand trends, increasing prevalence of chronic diseases, growth in chemotherapy and critical care procedures, rising adoption of home infusion therapy, technological advancements in smart pumps, and healthcare infrastructure investments. Regression-based analysis and trend modeling were applied to project future market growth and CAGR.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Cross-Segmentation Analysis for Intravenous Infusion Pumps by Product & Disease Indication
Detailed cross-segmentation analysis across intravenous infusion pump product categories including volumetric, syringe, insulin, ambulatory, enteral, patient-controlled analgesia (PCA), and implantable infusion pumps by disease indications such as chemotherapy, diabetes, hematology, gastroenterology, pediatrics/neonatology, and pain management. Assessment includes adoption trends across hospitals, ambulatory care settings, and home healthcare environments across key regions.
Enables clients to identify the highest-growth product-application combinations, evaluate demand shifts toward home-based and specialty infusion therapies, prioritize product development initiatives, and uncover high-potential therapeutic segments for commercialization.
Competitive Intelligence & Technology Benchmarking for Infusion Pump Manufacturers
Comprehensive benchmarking of leading infusion pump manufacturers based on smart pump capabilities, software interoperability, drug library integration, connectivity features, geographic presence, pricing strategies, distribution network, regulatory approvals, partnerships, and innovation pipelines. Analysis also covers competitive positioning across hospital, ambulatory, and home infusion segments.
Supports assessment of competitive positioning, identification of technology gaps and differentiation opportunities, evaluation of partnership and acquisition prospects, and development of effective market entry and expansion strategies.
Regional Demand Assessment & Healthcare Infrastructure Analysis
Customized regional and country-level market assessment covering North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with detailed analysis of chronic disease prevalence, healthcare infrastructure, reimbursement landscape, regulatory environment, adoption of smart infusion technologies, and home infusion penetration. Includes country-level demand forecasting for key infusion pump categories.
Helps clients identify high-growth regional markets, evaluate country-specific commercialization opportunities, optimize geographic expansion strategies, and align investments with evolving healthcare infrastructure and infusion therapy adoption trends.
Frequently Asked Questions About This Report
The pediatrics/neonatology segment held the largest revenue share of over 26.4% in 2025.
North America dominated the intravenous infusion pumps market with the largest revenue share of 51.0% in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The global intravenous infusion pumps market size was valued at USD 6.6 billion in 2025 and is estimated at USD 7.2 billion in 2026.
The global intravenous infusion pumps market is expected to grow at a CAGR of 8.9% from 2026 to 2033, reaching USD 13.0 billion by 2033.
The volumetric infusion pumps segment held the largest revenue share of over 16.8% in 2025.
Key players include Baxter; B. Braun Medical Inc.; Medtronic; Micrel Medical Devices SA; Boston Scientific Corporation; Cardinal Health; Fresenius Kabi AG; ICU Medical, Inc.; F. Hoffmann-La Roche Ltd; Tandem Diabetes Care, Inc.
The intravenous infusion pumps market is primarily driven by the rising prevalence of chronic diseases, increasing surgical procedures, and growing demand for precise and continuous drug delivery. In addition, the expanding adoption of home healthcare services and advancements in smart infusion pump technologies are further supporting market growth.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
